Takeda Pharmaceutical Co Ltd (TAK) income statement
TAKNYSEPharmaceutical PreparationsAlso trades as TKPHF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jun 17, 2026Score 5/30
$21.27−0.37 (-1.71%)
Close on Nov 18, 2026Market cap $73.30BP/E –Yield –
Takeda Pharmaceutical Co Ltd income statement
Ratios
Latest available, balances at Mar 31, 2026
Profitability, FY2026
- Gross margin
- 65.1%
- Operating margin
- 0.1%
- Net margin
- -3.4%
- Return on equity, FY2026
- -2.1%
Financial strength
- Current ratio
- 1.09
- Debt to equity
- 0.66
- Debt to assets
- 31.5%
- Cash to current liabilities
- 21.0%
Valuation
- P/E ratio
- –
- Price to sales
- 2.60
- Price to book
- 1.58
- Dividend yield
- –
See a number that looks wrong?